Bulletin: NRG Energy Inc. Ratings Unchanged Following Rejection Of Blackstone Offer For Dynegy Inc. Nov 10

  • ID: 1787452
  • November 2010
  • Standard & Poors
1 of 3


  • Dynegy Inc.
  • NRG Energy Inc.
  • MORE

SAN FRANCISCO (Standard & Poor's) Nov. 24, 2010--Standard & Poor's Ratings Services said today that the corporate credit rating and all issue debt ratings on NRG Energy Inc. (NRG; BB-/Stable/B-2) are unaffected following Dynegy Inc. (B-/Watch Neg/B-2) shareholders' rejection of The Blackstone Group's offer to buy all of Dynegy for $5 per share, up from $4.50 per share announced on Aug. 13, 2010. On Aug. 17, 2010, we affirmed the 'BB-' corporate credit rating and all issue ratings on NRG and assigned our 'BB-' rating to the company's proposed $750 million senior bond issue to finance the acquisition of 3.8 gigawatts of gas-fired assets from Dynegy, which were being sold in connection with the Blackstone offer. That transaction is now...

Companies mentioned in this report are:
- NRG Energy Inc.
- Dynegy Inc.

Action: Bulletin

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- NRG Energy Inc.
- Dynegy Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.